307 related articles for article (PubMed ID: 23534738)
1. Effects of FasL expression in oral squamous cell cancer.
Fang L; Sun L; Hu FF; Chen QE
Asian Pac J Cancer Prev; 2013; 14(1):281-5. PubMed ID: 23534738
[TBL] [Abstract][Full Text] [Related]
2. Suppression of Fas receptor and negative correlation of Fas ligand with differentiation and apoptosis in oral squamous cell carcinoma.
Loro LL; Vintermyr OK; Johannessen AC; Liavaag PG; Jonsson R
J Oral Pathol Med; 1999 Feb; 28(2):82-7. PubMed ID: 9950255
[TBL] [Abstract][Full Text] [Related]
3. Correlation of Fas/FasL expression to cell apoptosis in Epstein-Barr virus-associated gastric carcinoma.
He D; Xiao L; Chen JN; Liang Q; Shao CK
Chin J Cancer; 2010 Mar; 29(3):283-7. PubMed ID: 20193111
[TBL] [Abstract][Full Text] [Related]
4. The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma.
Bennett MW; O'Connell J; O'Sullivan GC; Brady C; Roche D; Collins JK; Shanahan F
J Immunol; 1998 Jun; 160(11):5669-75. PubMed ID: 9605174
[TBL] [Abstract][Full Text] [Related]
5. A Fas Ligand (FasL)-Fused Humanized Antibody Against Tumor-Associated Glycoprotein 72 Selectively Exhibits the Cytotoxic Effect Against Oral Cancer Cells with a Low FasL/Fas Ratio.
Chien MH; Chang WM; Lee WJ; Chang YC; Lai TC; Chan DV; Sharma R; Lin YF; Hsiao M
Mol Cancer Ther; 2017 Jun; 16(6):1102-1113. PubMed ID: 28292939
[TBL] [Abstract][Full Text] [Related]
6. Expression of ADAM10, Fas, FasL and Soluble FasL in Patients with Oral Squamous Cell Carcinoma (OSCC) and their Association with Clinical-Pathological Parameters.
Zepeda-Nuño JS; Guerrero-Velázquez C; Del Toro-Arreola S; Vega-Magaña N; Ángeles-Sánchez J; Haramati J; Pereira-Suárez AL; Bueno-Topete MR
Pathol Oncol Res; 2017 Apr; 23(2):345-353. PubMed ID: 27628319
[TBL] [Abstract][Full Text] [Related]
7. Signaling abnormalities, apoptosis, and reduced proliferation of circulating and tumor-infiltrating lymphocytes in patients with oral carcinoma.
Reichert TE; Strauss L; Wagner EM; Gooding W; Whiteside TL
Clin Cancer Res; 2002 Oct; 8(10):3137-45. PubMed ID: 12374681
[TBL] [Abstract][Full Text] [Related]
8. Mechanism of counterattack of colorectal cancer cell by Fas/Fas ligand system.
Zhu Q; Liu JY; Xu HW; Yang CM; Zhang AZ; Cui Y; Wang HB
World J Gastroenterol; 2005 Oct; 11(39):6125-9. PubMed ID: 16273638
[TBL] [Abstract][Full Text] [Related]
9. Fas receptor counterattack against tumor-infiltrating lymphocytes in vivo as a mechanism of immune escape in gastric carcinoma.
Koyama S; Koike N; Adachi S
J Cancer Res Clin Oncol; 2001 Jan; 127(1):20-6. PubMed ID: 11206267
[TBL] [Abstract][Full Text] [Related]
10. [Expression of Fas and Fas ligand in infiltrating lymphocytes in patients with oral lichen planus].
Lei L; Tan WX; Zhou XL; Zheng PE
Zhonghua Kou Qiang Yi Xue Za Zhi; 2010 Apr; 45(4):219-22. PubMed ID: 20654197
[TBL] [Abstract][Full Text] [Related]
11. Expression of Fas/FasL in patients with oral lichen planus.
Hadzi-Mihailovic M; Raybaud H; Monteil R; Jankovic L
J BUON; 2009; 14(3):487-93. PubMed ID: 19810143
[TBL] [Abstract][Full Text] [Related]
12. FAS ligand expression in inflammatory infiltrate lymphoid cells as a prognostic marker in oral squamous cell carcinoma.
Peterle GT; Santos M; Mendes SO; Carvalho-Neto PB; Maia LL; Stur E; Agostini LP; Silva CV; Trivilin LO; Nunes FD; Carvalho MB; Tajara EH; Louro ID; Silva-Conforti AM
Genet Mol Res; 2015 Sep; 14(3):11145-53. PubMed ID: 26400345
[TBL] [Abstract][Full Text] [Related]
13. Action and mechanism of Fas and Fas ligand in immune escape of gallbladder carcinoma.
Xu LN; Zou SQ; Wang JM
World J Gastroenterol; 2005 Jun; 11(24):3719-23. PubMed ID: 15968727
[TBL] [Abstract][Full Text] [Related]
14. Fas (Apo-1/CD95) and Fas ligand interaction between gastric cancer cells and immune cells.
Lee TB; Min YD; Lim SC; Kim KJ; Jeon HJ; Choi SM; Choi CH
J Gastroenterol Hepatol; 2002 Jan; 17(1):32-8. PubMed ID: 11895550
[TBL] [Abstract][Full Text] [Related]
15. High expression of EZH2 is associated with tumor proliferation and prognosis in human oral squamous cell carcinomas.
Kidani K; Osaki M; Tamura T; Yamaga K; Shomori K; Ryoke K; Ito H
Oral Oncol; 2009 Jan; 45(1):39-46. PubMed ID: 18619895
[TBL] [Abstract][Full Text] [Related]
16. Fas-mediated apoptosis of melanoma cells and infiltrating lymphocytes in human malignant melanomas.
Shukuwa T; Katayama I; Koji T
Mod Pathol; 2002 Apr; 15(4):387-96. PubMed ID: 11950912
[TBL] [Abstract][Full Text] [Related]
17. Expression of Fas ligand in gastric carcinoma relates to lymph node metastasis.
Nagashima H; Mori M; Sadanaga N; Mashino K; Yoshikawa Y; Sugimachi K
Int J Oncol; 2001 Jun; 18(6):1157-62. PubMed ID: 11351245
[TBL] [Abstract][Full Text] [Related]
18. Fas ligand-positive membranous vesicles isolated from sera of patients with oral cancer induce apoptosis of activated T lymphocytes.
Kim JW; Wieckowski E; Taylor DD; Reichert TE; Watkins S; Whiteside TL
Clin Cancer Res; 2005 Feb; 11(3):1010-20. PubMed ID: 15709166
[TBL] [Abstract][Full Text] [Related]
19. Fas ligand expression by neoplastic T lymphocytes mediates elimination of CD8+ cytotoxic T lymphocytes in mycosis fungoides: a potential mechanism of tumor immune escape?
Ni X; Hazarika P; Zhang C; Talpur R; Duvic M
Clin Cancer Res; 2001 Sep; 7(9):2682-92. PubMed ID: 11555580
[TBL] [Abstract][Full Text] [Related]
20. Expression of fas (CD95) ligand is correlated with IL-10 and granulocyte colony-stimulating factor expression in oral and oropharyngeal squamous cell carcinoma.
Fujieda S; Sunaga H; Tsuzuki H; Fan GK; Ito T; Sugimoto C; Saito H
Cancer Lett; 2000 Dec; 161(1):73-81. PubMed ID: 11078915
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
